NEUREN PHARMACEUTICALS LIMITED - Announcements

1.77%

$13.19

Market Cap $1.651B

Healthcare Biotechnology

Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing... Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing therapies for neurodevelopmental disorders. The Company is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product NNZ-2591 is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The Company has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of NNZ-259 for Rett syndrome and Fragile X syndrome.More

Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a dedicated mission to be at the heart of cancer care. WEBINAR: What investors should know about what it takes for ASX-listed companies to get medical developments...

Announcements

Filter Results

All Price Sensitive Only

NEU	Update - Notification of buy-back - NEU		16/05/25	15.43KB	Share
NEU	Update - Notification of buy-back - NEU		15/05/25	15.44KB	Share
NEU	Update - Notification of buy-back - NEU		14/05/25	15.44KB	Share
NEU	NEU receives FDA minutes and re-confirms Phase 3 endpoints		13/05/25	161.63KB	Share
NEU	Update - Notification of buy-back - NEU		13/05/25	15.44KB	Share
NEU	Update - Notification of buy-back - NEU		12/05/25	15.44KB	Share
NEU	Update - Notification of buy-back - NEU		09/05/25	15.43KB	Share
NEU	Update - Notification of buy-back - NEU		08/05/25	15.44KB	Share
NEU	DAYBUE Q1 2025 net sales US$84.6m up 11% from Q1 2024	PRICE SENSITIVE	08/05/25	238.53KB	Share
NEU	Update - Notification of buy-back - NEU		07/05/25	15.44KB	Share
NEU	Notification of cessation of securities - NEU		06/05/25	12.89KB	Share
NEU	Update - Notification of buy-back - NEU		06/05/25	15.43KB	Share
NEU	Becoming a substantial holder		05/05/25	757.8KB	Share
NEU	Update - Notification of buy-back - NEU		05/05/25	15.43KB	Share
NEU	Neuren appoints Daryl DeKarske to executive team		02/05/25	155.57KB	Share
NEU	Update - Notification of buy-back - NEU		02/05/25	15.43KB	Share
NEU	Update - Notification of buy-back - NEU		01/05/25	15.44KB	Share
NEU	Update - Notification of buy-back - NEU		30/04/25	15.44KB	Share
NEU	Update - Notification of buy-back - NEU		29/04/25	15.44KB	Share
NEU	Update - Notification of buy-back - NEU		28/04/25	15.43KB	Share
NEU	Virtual AGM online guide		24/04/25	305.83KB	Share
NEU	Notice of Annual General Meeting/Proxy Form		24/04/25	985.91KB	Share
NEU	Update - Notification of buy-back - NEU		24/04/25	15.44KB	Share
NEU	Update - Notification of buy-back - NEU		23/04/25	15.44KB	Share
NEU	Update - Notification of buy-back - NEU		22/04/25	15.44KB	Share
NEU	Update - Notification of buy-back - NEU		17/04/25	15.44KB	Share
NEU	Change of Director's Interest Notice - J Basile		16/04/25	178.46KB	Share
NEU	NEU confirms primary endpoints for Phase 3 trial in PMS	PRICE SENSITIVE	14/04/25	167.14KB	Share
NEU	Update - Notification of buy-back - NEU		07/04/25	15.43KB	Share
NEU	Update - Notification of buy-back - NEU		04/04/25	15.43KB	Share
NEU	Notification of cessation of securities - NEU		03/04/25	12.89KB	Share
NEU	Update - Notification of buy-back - NEU		03/04/25	15.43KB	Share
NEU	Appendix 4G		03/04/25	274.9KB	Share
NEU	2024 Annual Report to shareholders		03/04/25	1.8MB	Share
NEU	Update - Notification of buy-back - NEU		02/04/25	15.44KB	Share
NEU	Update - Notification of buy-back - NEU		01/04/25	15.44KB	Share
NEU	Update - Notification of buy-back - NEU		31/03/25	15.44KB	Share
NEU	Update - Notification of buy-back - NEU		28/03/25	15.44KB	Share
NEU	Neuren initiates development of NNZ-2591 to treat HIE	PRICE SENSITIVE	27/03/25	165.4KB	Share
NEU	Update - Notification of buy-back - NEU		27/03/25	15.44KB	Share
NEU	Update - Notification of buy-back - NEU		26/03/25	15.44KB	Share
NEU	Update - Notification of buy-back - NEU		25/03/25	15.44KB	Share
NEU	Update - Notification of buy-back - NEU		24/03/25	15.44KB	Share
NEU	Update - Notification of buy-back - NEU		21/03/25	15.44KB	Share
NEU	Update - Notification of buy-back - NEU		20/03/25	15.43KB	Share
NEU	Update - Notification of buy-back - NEU		19/03/25	15.42KB	Share
NEU	Update - Notification of buy-back - NEU		18/03/25	15.43KB	Share
NEU	Update - Notification of buy-back - NEU		17/03/25	15.43KB	Share
NEU	Update - Notification of buy-back - NEU		14/03/25	15.43KB	Share
NEU	Update - Notification of buy-back - NEU		13/03/25	15.43KB	Share
NEU	Update - Notification of buy-back - NEU		12/03/25	15.43KB	Share
NEU	Becoming a substantial holder		12/03/25	895.3KB	Share
NEU	Application for quotation of securities - NEU		11/03/25	14.25KB	Share
NEU	Update - Notification of buy-back - NEU		11/03/25	15.43KB	Share
NEU	Update - Notification of buy-back - NEU		10/03/25	15.43KB	Share
NEU	Notification of cessation of securities - NEU		07/03/25	12.89KB	Share
NEU	Update - Notification of buy-back - NEU		07/03/25	15.43KB	Share
NEU	Update - Notification of buy-back - NEU		06/03/25	15.43KB	Share
NEU	Ceasing to be a substantial holder		06/03/25	191.06KB	Share
NEU	Update - Notification of buy-back - NEU		05/03/25	15.43KB	Share
NEU	Update - Notification of buy-back - NEU		04/03/25	15.43KB	Share
NEU	Notification of cessation of securities - NEU		03/03/25	12.8KB	Share
NEU	2024 Full Year Results webinar		28/02/25	1.19MB	Share
NEU	Neuren receives DAYBUE sales milestone payment of US$50m	PRICE SENSITIVE	28/02/25	209.92KB	Share
NEU	2024 results - A$166m comprehensive income for shareholders	PRICE SENSITIVE	28/02/25	331.89KB	Share
NEU	Appendix 4E and 2024 full year accounts	PRICE SENSITIVE	28/02/25	373.96KB	Share
NEU	Neuren 2024 results investor webinar on 28 February 2025		27/02/25	158.69KB	Share
NEU	DAYBUE (trofinetide) 2024 net sales US$348 million	PRICE SENSITIVE	27/02/25	230.36KB	Share
NEU	Becoming a substantial holder		25/02/25	277.14KB	Share
NEU	Neuren receives Rare Pediatric Disease Designation from FDA	PRICE SENSITIVE	24/02/25	155.8KB	Share
NEU	Fast Track granted by FDA for NNZ-2591 in Pitt Hopkins	PRICE SENSITIVE	19/02/25	213.15KB	Share
NEU	Priority Review Voucher sale proceeds received	PRICE SENSITIVE	07/02/25	154.98KB	Share
NEU	Type C Meeting granted by FDA for Phelan-McDermid syndrome		07/02/25	155.37KB	Share
NEU	Neuren to present at autism research meeting		06/02/25	259.26KB	Share
NEU	NEU Presentations at ACMG Annual Clinical Genetics Meeting		22/01/25	267.42KB	Share
NEU	J.P. Morgan Healthcare Conference recap		20/01/25	160.21KB	Share
NEU	Neuren JP Morgan Healthcare Conference 2025 presentation		16/01/25	1.29MB	Share
NEU	Trofinetide marketing application submitted in Europe	PRICE SENSITIVE	15/01/25	188.38KB	Share
NEU	Update - Notification of buy-back - NEU		18/12/24	15.43KB	Share
NEU	Update - Notification of buy-back - NEU		17/12/24	15.43KB	Share
NEU	Update - Notification of buy-back - NEU		16/12/24	15.43KB	Share
NEU	Update - Notification of buy-back - NEU		13/12/24	15.42KB	Share
NEU	Priority Review Voucher sale complete		12/12/24	181.47KB	Share
NEU	Update - Notification of buy-back - NEU		12/12/24	15.42KB	Share
NEU	Update - Notification of buy-back - NEU		11/12/24	15.43KB	Share
NEU	Update - Notification of buy-back - NEU		10/12/24	15.42KB	Share
NEU	Update - Notification of buy-back - NEU		09/12/24	15.43KB	Share
NEU	Update - Notification of buy-back - NEU		06/12/24	15.43KB	Share
NEU	Update - Notification of buy-back - NEU		05/12/24	15.42KB	Share
NEU	Update - Notification of buy-back - NEU		04/12/24	15.42KB	Share
NEU	Update - Notification of buy-back - NEU		03/12/24	15.41KB	Share
NEU	Investor presentation, 15 November 2024		15/11/24	1.44MB	Share
NEU	Notification of buy-back - NEU		14/11/24	12.79KB	Share
NEU	Neuren announces A$50m on-market share buy-back program	PRICE SENSITIVE	14/11/24	161.11KB	Share
NEU	Q3 2024 update	PRICE SENSITIVE	07/11/24	287.04KB	Share
NEU	Pause in Trading	PRICE SENSITIVE	07/11/24	113.54KB	Share
NEU	PRV sold for US$150m - Neuren to receive one third	PRICE SENSITIVE	06/11/24	181.53KB	Share
NEU	Updated Share Trading Policy		01/11/24	287.87KB	Share
NEU	Notification of cessation of securities - NEU		28/10/24	12.81KB	Share
NEU	DAYBUE receives marketing authorization in Canada	PRICE SENSITIVE	17/10/24	253.08KB	Share

NEU Update - Notification of buy-back - NEU
16/05/25		15.43KB	Share
NEU Update - Notification of buy-back - NEU
15/05/25		15.44KB	Share
NEU Update - Notification of buy-back - NEU
14/05/25		15.44KB	Share
NEU NEU receives FDA minutes and re-confirms Phase 3 endpoints
13/05/25		161.63KB	Share
NEU Update - Notification of buy-back - NEU
13/05/25		15.44KB	Share
NEU Update - Notification of buy-back - NEU
12/05/25		15.44KB	Share
NEU Update - Notification of buy-back - NEU
09/05/25		15.43KB	Share
NEU Update - Notification of buy-back - NEU
08/05/25		15.44KB	Share
NEU DAYBUE Q1 2025 net sales US$84.6m up 11% from Q1 2024
08/05/25	PRICE SENSITIVE	238.53KB	Share
NEU Update - Notification of buy-back - NEU
07/05/25		15.44KB	Share
NEU Notification of cessation of securities - NEU
06/05/25		12.89KB	Share
NEU Update - Notification of buy-back - NEU
06/05/25		15.43KB	Share
NEU Becoming a substantial holder
05/05/25		757.8KB	Share
NEU Update - Notification of buy-back - NEU
05/05/25		15.43KB	Share
NEU Neuren appoints Daryl DeKarske to executive team
02/05/25		155.57KB	Share
NEU Update - Notification of buy-back - NEU
02/05/25		15.43KB	Share
NEU Update - Notification of buy-back - NEU
01/05/25		15.44KB	Share
NEU Update - Notification of buy-back - NEU
30/04/25		15.44KB	Share
NEU Update - Notification of buy-back - NEU
29/04/25		15.44KB	Share
NEU Update - Notification of buy-back - NEU
28/04/25		15.43KB	Share
NEU Virtual AGM online guide
24/04/25		305.83KB	Share
NEU Notice of Annual General Meeting/Proxy Form
24/04/25		985.91KB	Share
NEU Update - Notification of buy-back - NEU
24/04/25		15.44KB	Share
NEU Update - Notification of buy-back - NEU
23/04/25		15.44KB	Share
NEU Update - Notification of buy-back - NEU
22/04/25		15.44KB	Share
NEU Update - Notification of buy-back - NEU
17/04/25		15.44KB	Share
NEU Change of Director's Interest Notice - J Basile
16/04/25		178.46KB	Share
NEU NEU confirms primary endpoints for Phase 3 trial in PMS
14/04/25	PRICE SENSITIVE	167.14KB	Share
NEU Update - Notification of buy-back - NEU
07/04/25		15.43KB	Share
NEU Update - Notification of buy-back - NEU
04/04/25		15.43KB	Share
NEU Notification of cessation of securities - NEU
03/04/25		12.89KB	Share
NEU Update - Notification of buy-back - NEU
03/04/25		15.43KB	Share
NEU Appendix 4G
03/04/25		274.9KB	Share
NEU 2024 Annual Report to shareholders
03/04/25		1.8MB	Share
NEU Update - Notification of buy-back - NEU
02/04/25		15.44KB	Share
NEU Update - Notification of buy-back - NEU
01/04/25		15.44KB	Share
NEU Update - Notification of buy-back - NEU
31/03/25		15.44KB	Share
NEU Update - Notification of buy-back - NEU
28/03/25		15.44KB	Share
NEU Neuren initiates development of NNZ-2591 to treat HIE
27/03/25	PRICE SENSITIVE	165.4KB	Share
NEU Update - Notification of buy-back - NEU
27/03/25		15.44KB	Share
NEU Update - Notification of buy-back - NEU
26/03/25		15.44KB	Share
NEU Update - Notification of buy-back - NEU
25/03/25		15.44KB	Share
NEU Update - Notification of buy-back - NEU
24/03/25		15.44KB	Share
NEU Update - Notification of buy-back - NEU
21/03/25		15.44KB	Share
NEU Update - Notification of buy-back - NEU
20/03/25		15.43KB	Share
NEU Update - Notification of buy-back - NEU
19/03/25		15.42KB	Share
NEU Update - Notification of buy-back - NEU
18/03/25		15.43KB	Share
NEU Update - Notification of buy-back - NEU
17/03/25		15.43KB	Share
NEU Update - Notification of buy-back - NEU
14/03/25		15.43KB	Share
NEU Update - Notification of buy-back - NEU
13/03/25		15.43KB	Share
NEU Update - Notification of buy-back - NEU
12/03/25		15.43KB	Share
NEU Becoming a substantial holder
12/03/25		895.3KB	Share
NEU Application for quotation of securities - NEU
11/03/25		14.25KB	Share
NEU Update - Notification of buy-back - NEU
11/03/25		15.43KB	Share
NEU Update - Notification of buy-back - NEU
10/03/25		15.43KB	Share
NEU Notification of cessation of securities - NEU
07/03/25		12.89KB	Share
NEU Update - Notification of buy-back - NEU
07/03/25		15.43KB	Share
NEU Update - Notification of buy-back - NEU
06/03/25		15.43KB	Share
NEU Ceasing to be a substantial holder
06/03/25		191.06KB	Share
NEU Update - Notification of buy-back - NEU
05/03/25		15.43KB	Share
NEU Update - Notification of buy-back - NEU
04/03/25		15.43KB	Share
NEU Notification of cessation of securities - NEU
03/03/25		12.8KB	Share
NEU 2024 Full Year Results webinar
28/02/25		1.19MB	Share
NEU Neuren receives DAYBUE sales milestone payment of US$50m
28/02/25	PRICE SENSITIVE	209.92KB	Share
NEU 2024 results - A$166m comprehensive income for shareholders
28/02/25	PRICE SENSITIVE	331.89KB	Share
NEU Appendix 4E and 2024 full year accounts
28/02/25	PRICE SENSITIVE	373.96KB	Share
NEU Neuren 2024 results investor webinar on 28 February 2025
27/02/25		158.69KB	Share
NEU DAYBUE (trofinetide) 2024 net sales US$348 million
27/02/25	PRICE SENSITIVE	230.36KB	Share
NEU Becoming a substantial holder
25/02/25		277.14KB	Share
NEU Neuren receives Rare Pediatric Disease Designation from FDA
24/02/25	PRICE SENSITIVE	155.8KB	Share
NEU Fast Track granted by FDA for NNZ-2591 in Pitt Hopkins
19/02/25	PRICE SENSITIVE	213.15KB	Share
NEU Priority Review Voucher sale proceeds received
07/02/25	PRICE SENSITIVE	154.98KB	Share
NEU Type C Meeting granted by FDA for Phelan-McDermid syndrome
07/02/25		155.37KB	Share
NEU Neuren to present at autism research meeting
06/02/25		259.26KB	Share
NEU NEU Presentations at ACMG Annual Clinical Genetics Meeting
22/01/25		267.42KB	Share
NEU J.P. Morgan Healthcare Conference recap
20/01/25		160.21KB	Share
NEU Neuren JP Morgan Healthcare Conference 2025 presentation
16/01/25		1.29MB	Share
NEU Trofinetide marketing application submitted in Europe
15/01/25	PRICE SENSITIVE	188.38KB	Share
NEU Update - Notification of buy-back - NEU
18/12/24		15.43KB	Share
NEU Update - Notification of buy-back - NEU
17/12/24		15.43KB	Share
NEU Update - Notification of buy-back - NEU
16/12/24		15.43KB	Share
NEU Update - Notification of buy-back - NEU
13/12/24		15.42KB	Share
NEU Priority Review Voucher sale complete
12/12/24		181.47KB	Share
NEU Update - Notification of buy-back - NEU
12/12/24		15.42KB	Share
NEU Update - Notification of buy-back - NEU
11/12/24		15.43KB	Share
NEU Update - Notification of buy-back - NEU
10/12/24		15.42KB	Share
NEU Update - Notification of buy-back - NEU
09/12/24		15.43KB	Share
NEU Update - Notification of buy-back - NEU
06/12/24		15.43KB	Share
NEU Update - Notification of buy-back - NEU
05/12/24		15.42KB	Share
NEU Update - Notification of buy-back - NEU
04/12/24		15.42KB	Share
NEU Update - Notification of buy-back - NEU
03/12/24		15.41KB	Share
NEU Investor presentation, 15 November 2024
15/11/24		1.44MB	Share
NEU Notification of buy-back - NEU
14/11/24		12.79KB	Share
NEU Neuren announces A$50m on-market share buy-back program
14/11/24	PRICE SENSITIVE	161.11KB	Share
NEU Q3 2024 update
07/11/24	PRICE SENSITIVE	287.04KB	Share
NEU Pause in Trading
07/11/24	PRICE SENSITIVE	113.54KB	Share
NEU PRV sold for US$150m - Neuren to receive one third
06/11/24	PRICE SENSITIVE	181.53KB	Share
NEU Updated Share Trading Policy
01/11/24		287.87KB	Share
NEU Notification of cessation of securities - NEU
28/10/24		12.81KB	Share
NEU DAYBUE receives marketing authorization in Canada
17/10/24	PRICE SENSITIVE	253.08KB	Share

REFRESH

1 2 3 4 5 6

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $13.19		Change 0.230(1.77%)		Mkt cap ! $1.651B

Open	High	Low	Value	Volume
$13.08	$13.50	$13.01	$4.957M	374.2K

Buyers (Bids)

No.	Vol.	Price($)
1	16	$13.18

Sellers (Offers)

Price($)	Vol.	No.
$13.19	1998	1

View Market Depth

No.	Vol.	Price($)
1	76	13.050
1	500	13.030
1	450	13.010
2	2012	12.850
3	1245	12.800

Price($)	Vol.	No.
13.190	1998	1
13.250	1606	1
13.300	5500	2
13.350	674	2
13.400	12844	4

Last trade - 16.10pm 16/05/2025 (20 minute delay)

NEU (ASX) Chart

NEUREN PHARMACEUTICALS LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories